Jon Paul Gockerman

My research effort is involved in clinical research studies through the CALGB as well as several sub interests. My interest is the use of 131I MIBG in the treatment of carcinoids. We have completed a dose seeking study to determine the maximum tolerated dose. This has been completed and this paper is in preparation for publication. We plan to do an additional study of randomization in patients with this agent to see if we can determine an objective response rate in a controlled group of patients.

The secondary issue is that of high dose chemotherapy in lymphoma. We have completed a study involving use of high dose chemotherapy in a transplant setting in patients with refractory lymphoma. This study has treated over 100 patients and is in the process of being written up.